Analyst Pin-board DBD – Strong performance in 1H
|
· Revenue and NPAT in 6M were VND 600 billion (-5.1% YoY) and VND 94 billion (+16% YoY), completing 42% and 64% of annual plans, respectively. The annual revenue target is hard to achieve due to the pandemic, however, DBD expects the NPAT target can be fulfilled. · New anti-cancer medicine factory’s construction process has been completed and DBD expect it can obtain EU-GMP for an injection production line in 1Q2022. · Anti-cancer medicine revenue increased strongly by 51% YoY in 1H, contributing 15% to total revenue. · DBD aims to rise its market share in the dialysis fluid segment from 11% in 2020 to 30% in 2025. |
Viet Dragon Securities belongs to top 20 biggest securities companies in terms of chartered capital in Vietnam. With a qualified, dedicated and professional team, a widespread network, advanced technology, diversified products and services, and good relationship with local and foreign institutions, we provide a wide range of services and products to our clients both individuals and institutions, both local and foreign. We commit to provide our clients with promising investment opportunities and a comprehensive and professional financial investment services.
RongViet Research reports are diversified and abundant, along with in-depth analysis and performed by experienced, highly-qualified and knowledgeable teams. With the objectives of transparency, accurate and timely manner, RongViet believes that our products would always be important sources of information for customers/investors’ investment decisions.”
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.